Form 4: Eloxx Pharmaceuticals Director Acquires 30,000 Shares Through RSU Vesting

Eloxx Pharmaceuticals director Sumit Aggarwal acquired 30,000 shares of common stock through the vesting of restricted stock units on January 24, 2025.

Summary

• Sumit Aggarwal, a director at Eloxx Pharmaceuticals, acquired 30,000 shares of common stock.
• The acquisition occurred on January 24, 2025, through the vesting of restricted stock units (RSUs).
• The RSUs were granted previously and vest over time, with 50% vesting on the first anniversary of January 24, 2024, and the remainder in two equal annual installments.
• Following the transaction, Mr. Aggarwal directly owns 199,930 shares of Eloxx common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation. It is a positive sign that the director is meeting the vesting conditions, but it is not a major event that would significantly impact the company's outlook.

Positives

• The vesting of RSUs indicates that the director is meeting the conditions of their compensation package.
• The increase in share ownership aligns the director's interests with those of the shareholders.

Industry Context

This is a standard transaction for company directors who receive equity compensation as part of their overall package. It is common for directors to receive restricted stock units that vest over time.

Comparison to Industry Standards

• Equity compensation, such as restricted stock units, is a common practice for directors and executives in publicly traded companies, including those in the pharmaceutical industry.
• The vesting schedule of the RSUs, with 50% vesting on the first anniversary and the remainder in two equal annual installments, is a typical vesting structure.
• Similar companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also use equity-based compensation for their directors and executives.

Stakeholder Impact

• The transaction increases the director's alignment with shareholder interests.
• The vesting of RSUs is a standard part of executive compensation and is not expected to have a significant impact on other stakeholders.

Key Dates

Keywords

Eloxx Pharmaceuticals, Sumit Aggarwal, restricted stock units, RSU, share acquisition, director, insider trading, beneficial ownership